Hemoglobinopathies Clinical Trial
Official title:
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
The study uses reduced intensity conditioning that is immune suppressive to achieve donor cell engraftment without exposure to radiation or high dose chemotherapy in children with non-malignant disorders. The intent is to minimize early and late regimen related toxicities in the context of a reduced intensity regimen. In addition to maximizing opportunity for donor cell engraftment, the trial seeks to minimize toxicities associated with transplant such as graft versus host disease and employs GVHD prophylaxis that seeks to decrease rates of acute and chronic GVHD in the setting of matched and mismatched donor stem cell transplants from marrow and cord blood sources. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Recruiting |
NCT06107400 -
Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
|
Early Phase 1 | |
Enrolling by invitation |
NCT02986698 -
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
|
Phase 1 | |
Completed |
NCT00744692 -
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
|
Phase 1 | |
Recruiting |
NCT05799118 -
Study of the Role of Genetic Modifiers in Hemoglobinopathies
|
||
Active, not recruiting |
NCT03745287 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00673608 -
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
|
Phase 4 | |
Recruiting |
NCT04644016 -
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
|
Phase 2 | |
Recruiting |
NCT04853576 -
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05356195 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
|
Phase 3 | |
Completed |
NCT03609840 -
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Active, not recruiting |
NCT01850108 -
Non-Myeloablative Conditioning and Bone Marrow Transplantation
|
N/A | |
Recruiting |
NCT05329649 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
|
Phase 3 | |
Active, not recruiting |
NCT01966367 -
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT00153985 -
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
|
Phase 2 | |
Recruiting |
NCT03128996 -
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT03149289 -
Hepatitis C Virus Infection in Patients With Hemoglobinopathies
|
N/A | |
Completed |
NCT00000588 -
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
|
Phase 2 |